Đang chuẩn bị liên kết để tải về tài liệu:
Study of cell differentiation by phylogenetic analysis using histone modification data

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

In cell differentiation, a cell of a less specialized type becomes one of a more specialized type, even though all cells have the same genome. Transcription factors and epigenetic marks like histone modifications can play a significant role in the differentiation process. |

TÀI LIỆU LIÊN QUAN

Clinical significance of BCL2, C-MYC, and BCL6 genetic abnormalities, epstein barr virus infection, CD5 protein expression, germinal center B cell non germinal center B cell subtypes, Co-expression of MYC/BCL2 proteins and Co-expression of MYC/BCL2/BCL6 proteins in diffuse large B-cell lymphoma: A clinical and pathological correlation study of 120 patients

Outcome and prospective factor analysis of high-dose therapy combined with autologous peripheral blood stem cell transplantation in patients with peripheral T-cell lymphomas

A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: Rationale and study protocol design for the LOGIK1702 study

Study on PET/CT findings in patients with small cell lung cancer

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

Evaluation of CD68 in oral squamous cell carcinoma and their relation with clinicopathological parameters –An immunohistochemical study

The WIRE study a phase II, multi-arm, multicentre, non-randomised window-ofopportunity clinical trial platform using a Bayesian adaptive design for proof-ofmechanism of novel treatment strategies in operable renal cell cancer – a study protocol

The PRO-RCC study: A long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: A study based on TCGA and SEER database